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Abstract
Metal complexation can have a major influence on the antiviral and co-receptor binding properties
of cyclam and bicyclam macrocycles. We report the synthesis of the vanadyl cyclam complexes
[V(IV) O(cyclam)SO4] (1) and [V(IV)O(cyclam)Cl]Cl - (2), and the analogous xylylbicyclam sulfato
(3) and chlorido (4) complexes. The X-ray crystal structures of 1·1.33CH3OH and
2·CH3OH1.5H2O show short V=O bonds (1.6093(19) and 1.599(3) Å, respectively) with
monodentate sulfate H-bonded to ring NH groups for 1, but a long V-Cl bond (2.650(12) Å) for 2.
The solid-state structures of 3 and 4 were compared to those of 1 and 2 using vanadium K-edge
EXAFS data. These suggested that complex 4 was oligomeric and contained bridging chlorido
ligands. EPR studies suggested that the SO42- (from 1) and Cl- (from 2) ligands are readily substituted
by water in solution, whereas these remain partially bound for the VIV xylylbicyclam complexes 3
and 4. The vanadyl xylylbicyclam complexes were highly active against HIV-1 (IIIB) and HIV-2
(ROD) strains with IC50 values in the range 1-5 μM for 3 and 0.1-0.3 μM for 4; in contrast the vanadyl
cyclam complexes 1 and 2 were inactive. The factors which contribute to the activity of these
complexes are discussed. Studies of vanadyl cyclam docked into a model of the human CXCR4 co-
receptor revealed that the coordination of vanadium to the carboxylate of Asp171 may be
accompanied by H-bonding to the macrocycle and an attractive V=O··H interaction involving the
backbone Trp195 α-carbon proton of CXCR4. In addition, hydrophobic interactions with Trp195 are
present. Both ring configuration and the xylyl linker may play roles in determining the higher activity
of the bicyclam complexes.
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Macrocycles such as cyclam derivatives show promise as stem cell mobilizers and antivirals,
including activity against HIV and related AIDS disease. Drug treatments used today against
HIV infection are primarily associated with post-infection and classified as (i) reverse
transcriptase inhibitors (RTIs) - antiretroviral drugs that inhibit the enzyme reverse
transcriptase, essential for successful replication of HIV, (ii) protease inhibitors that inhibit the
function of HIV-1 protease, and (iii) integrase inhibitors such as Raltegravir, FDA-approved
in 2007 for the treatment of HIV-infections.1 A fourth class of antiviral agents known as entry
inhibitors, target the pre-infection cycle of HIV. Maraviroc is an entry inhibitor that specifically
targets the chemokine receptor, CCR5. Importantly, Pfizer's Celsentri® (maraviroc), is the first
new oral class of HIV treatment and was licensed by the European Agency for the Evaluation
of Medicinal Products (EMEA) in September 2007. Currently, all other available oral HIV
medicines target HIV only after it has entered the immune cells.2
The biological targets of entry inhibitor drugs are specific protein receptors expressed on the
surface of helper T-cells (a type of white blood cell or leukocyte) found in the immune system.
CD4 is a glycoprotein receptor and the primary receptor used by HIV-1 to gain entry to host
cells.3-5 Binding of the virus to CD4 occurs through attachment of the viral envelope
glycoprotein gp120, and through this association the virus gains access to the coreceptor
CXCR4, an important coreceptor for HIV-1.1 Interaction with CXCR4 enables the virus to
fuse with the cell membrane, gaining entry to the cell where it effectively discharges the viral
RNA, leading to replication and the onset of infection. CXCR4 is associated with HIV infection
during the later stages of AIDS disease when the immune system deteriorates rapidly.
The small molecule CXCR4 chemokine antagonist xylylbicyclam (Chart 1; AMD3100)
reached Phase II clinical trials as an entry inhibitor drug against HIV (IC50 < 0.1 μM). It has
since been further pursued as a stem cell mobilizer.6 The product has since been relaunched
commercially under the name of Mozobil having completed Phase III clinical trials as a stem
cell mobilizer and was approved for clinical use in the US in December 2008. The same
membrane protein CXCR4 that aids entry of HIV to cells also anchors stem cells in the bone
marrow. Mobilization of stem cells is beneficial during, for example, transplant therapy.
Cyclam macrocycles can bind strongly to d-block metal ions.7-10 The specific configurations
adopted by metal cyclam complexes11 (Chart 1) may be important for receptor recognition and
biological activity12 and it seems likely that the various configurations of metallo-cyclams are
recognised differently by the co-receptor. Zinc(II) in particular is abundant in the blood plasma
(ca. 19 μM) and the binding of xylylbicyclam to zinc(II) may play a role in its mechanism of
action.13-17 Indeed zinc complexes with configurationally constrained bicyclam ligands9 can
exhibit higher activity against HIV-1 than AMD3100. Recognition of metallocyclams such as
Zn(II)-xylylbicyclam by the CXCR4 coreceptor is thought to involve a combination of direct
coordination to side chains (Asp, Glu), hydrogen-bonding to cyclam NH groups and
hydrophobic interactions (with the periphery of the cyclam rings and the xylyl linker).12, 18
Here we describe the role of axial interactions with the metal by introducing the vanadyl
fragment (VO2+) into the cyclam ring. This new class of complexes introduces a different
application for the bioinorganic chemistry of vanadium, and complements the wealth of
vanadium research involving insulin-enhancing agents, cofactors in haloperoxidases, catalysts
and nitrogenase cofactors.19-21 There appears to be little previously reported work on vanadyl
cyclams. We have studied both cyclam and xylylbicyclam complexes with additional chloride
and sulfate ligands using a variety of techniques including X-ray crystallography, XANES,
EXAFS, EPR and molecular modelling. The anti-HIV activity of these vanadyl cyclam and
xylylbicyclam complexes was also determined.
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Cyclam (1,4,8,11-tetraazacyclotetradecane), α,α′-dibromo-p-xylene, ethyl trifluoroacetate,
triethylamine, barium chloride, vanadyl sulfate hydrate were purchased from Aldrich Chemical
Co. and were reagent grade unless otherwise stated.
Synthesis of oxovanadium(IV)-cyclam sulfate, 1
Cyclam, (0.91 g, 4.56 mmol) was dissolved in HPLC grade methanol (35 mL) and refluxed
under N2 for 10 min. Vanadyl sulfate hydrate (1.07 g, 4.56 mmol, 1 mol. equiv.) was added
and the reaction refluxed for 24 h. On stirring, a color change was observed from blue to green
after 1 min and to grey after 3 min. After 15 min the solution turned cloudy green and after 30
min was blue/grey in color. After 2.5 h this color deepened to a dark blue/grey. The solution
settled into two layers. The top layer was a vivid green in color and a blue precipitate settled
out as the bottom layer. The top layer was separated by centrifugation and then filtration, and
the solvent removed under reduced pressure to give a green powder (yield: 1.50 g, 4.13 mmol,
90.6%). The product was further dried under vacuum.
Anal. Calc. for C10H24N4VSO5·MeOH·0.5H2O: %C, 32.70; %H, 6.23; %N, 13.86. Found %
C, 32.43; %H, 6.49; %N, 14.46. ESI-MS: m/z = 363.90 [M+H]+; νmax (KBr)/cm-1 V=O, 974;
SO4, ν3 1106, 1064, 1028; ν4 619, 598.
Crystals of 1·1.33CH3OH suitable for X-ray diffraction were obtained by slow diffusion of
ether into a methanolic solution of the product at 277 K.
Synthesis of oxovanadium(IV)-cyclam dichloride, 2
Oxovanadium(IV)-cyclam, 1 (0.73 g, 0.21 mmol), was dissolved in distilled water (10 mL)
and barium chloride (0.63 g, 0.30 mmol, 3 mol. equiv. excess) added as an aqueous solution
(4 mL). A white precipitate formed immediately and the mixture was stirred at room
temperature in air for 16 h. The mixture was separated using centrifugal force (4000 rpm, 1 h)
and the green solution filtered. The solvent was removed under reduced pressure and further
dried under vacuum to give a crystalline green powder. Anal. Calc. for C10H24N4VOCl2·H2O
%C, 33.70; %H, 7.35; %N, 15.70. Found %C, 34.04; %H, 7.22; %N, 16.05. ESI-MS: m/z =
302.10 (Cl35), 304.00 (Cl37) [M]+; νmax (KBr)/cm-1 V=O, 945. Crystals of 2·CH3OH·1.5H2O
suitable for X-ray diffraction were formed by slow diffusion of ether into a methanolic solution
of the product at 277 K. Yield of crystals 0.03 g, 0.08 mmol, 36.6%.
Synthesis of oxovanadium(IV)-(xylylbicyclam) disulfate, 3
Xylylbicyclam (0.05 g, 0.10 mmol) was dissolved in 5 mL anhydrous methanol and refluxed
gently under argon for 5 min. Vanadyl sulfate hydrate (0.05 g, 0.20 mmol, 2 mol. equiv.) was
added and a color change was observed, both in the solution and in the solid added. After 3
min the initial clear solution began to turn green and the blue solid (vanadyl sulfate hydrate)
turned grey. After 15 min, the reaction became more homogenous and the color darkened to
brown. On standing, the flask contents settled into two layers and a pale green solution formed
on top of the dark solid. The reaction was refluxed for 16 h and the solution on standing was
green in color. The dark solid changed color to light blue. The green solution was separated
from the blue solid under centrifugal force, 4000 rpm, 1 h and the solvent removed under
reduced pressure and further dried under vacuum. The product dried to give a dark green
powder (0.05 g, 0.06 mmol, 61.9%).
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Anal. calc. for C28H54N8V2S2O10·MeOH·3H2O, %C, 38.07; %H, 7.05; %N, 12.25. Found %
C, 37.53; %H, 7.29; %N, 11.67. ESI-MS: m/z = 829.1 [M+H]+; νmax (K/Br)cm-1 V=O 945;
SO42- ν3 1120, 1034; ν4 615.
Synthesis of oxovanadium(IV)-(xylylbicyclam) tetrachloride, 4
Oxovanadium(IV)-(xylylbicyclam)-sulfate 3, (0.05 g, 0.06 mmol) was dissolved in water (3
mL) and heated until fully dissolved. Barium chloride (0.03 g, 0.12 mmol, 2 mol. equiv.) was
added as an aqueous solution (2 mL) and a cloudy solution formed immediately. The mixture
was stirred for 16 h at room temperature then separated under centrifugal force to give a green
solution and a blue solid. The green solution was decanted, filtered and the solvent was removed
by freeze-drying. On drying, a color change was noted from green to brown, and on redissolving
in water a green solution was obtained (yield: 0.04 g, 4.50 mmol, 75%).
Anal. calc. for C28H54N8V2Cl2O2·5H2O·2NaCl, %C, 36.77; %H, 7.05; %N, 12.25. Found %
C, 37.09; %H, 7.02; %N, 11.53.
ESI-MS: m/z = 705.4 [M-2Cl]2+ (100%), 741.3 [M-Cl]+; νmax (K/Br)cm-1 V=O 964.
X-ray crystallography
Diffraction data for compound 1 and 2 were collected at 150 K using a Bruker Smart Apex
CCD diffractometer. Absorption corrections for all data sets were performed with the multi-
scan procedure SADABS.22 Both structures were solved by direct methods (SHELXS or
SIR92).23, 24 Refinement was against F2 using all data (CRYSTALS).25 Unless stated
otherwise H-atoms were placed in geometrically calculated positions. In complex 1, one of the
molecules of methanol of solvation was disordered over 3 sites about a three-fold axis, and no
H-atoms were placed on this part of the structure. A second molecule of methanol of solvation
was on a general position; the hydroxyl H-atom on this molecule was located in a difference
map and refined. In complex 2, H atoms attached to oxygen were also located in a difference
map. H-atom positions were initially refined subject to restraints and thereafter allowed to ride
on their parent atoms. The programs Diamond 3.02026, Mercury 1.4.127 and ORTEP 3228 were
used for analysis of data and production of graphics. X-ray crystallographic data have been
deposited in the Cambridge Crystallographic Data Centre under the accession numbers CCDC
748340 and 748341.
IR spectroscopy
Infrared spectra were recorded as KBr pellets in the range 4000–400 cm-1 on a Perkin-Elmer
Paragon 1000 Fourier-transform spectrometer.
X-ray absorption spectroscopy
X-ray absorption spectra were recorded at Stanford Synchrotron Radiation Laboratory (SSRL)
on the 20-pole wiggler beam line 7-3, under ring operating conditions of 80-100 mA and 3
GeV. Data were collected using a Si (220) phi = 0° double crystal monochromator and the
signal was detected using a 30 element Ge detector array. All samples were prepared by lightly
grinding 5 mg of vanadium complex with boron nitride in a mortar and pestle until a fine
uniform powder was formed. XAS data were collected in the energy range from 5235-6485
eV using XAS Collect software. Ten scans of each compound were obtained at the V K edge,
to ensure reproducibility. Energy calibration was performed using the V K-edge spectrum of
a vanadium metal foil, assuming the lowest energy peak to be 5465 eV. Data processing,
including averaging scans, energy calibration, background subtraction and normalization was
performed in SixPACK.29 EXAFS analysis was carried out using Artemis.30
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EPR spectra were recorded on an X-band Bruker ER200D-SCR spectrometer connected to a
Datalink 486DX PC with EPR Acquisition System, version 2.42 software. Measurements were
recorded in fluid solution at 298 K and in frozen solution at 77 K. Data were simulated using
Bruker WINEPR Simphonia version 1.26 software by the National EPR Centre, University of
Manchester, UK and corrected as for the DPPH (2,2-diphenyl-1-picrylhydrazyl) standard.31
Antiviral testing
Experimental protocols for anti-HIV testing are detailed in Supporting Information.32
Molecular modeling
Our previously reported homology model of CXCR412 was used for manual docking of
oxovanadium(IV) cyclam complex 1 under the SYBYL version 6.9 (Tripos Associates, St.
Louis, MO) modelling environment. Complex 1 was first superimposed onto one ring of the
previously docked [Zn2-xylylbicyclam]-CXCR4 interaction12 using all equivalent Cα atoms
(crystal structures for both vanadium bicyclams complexes 3,4 were unavailable). The
vanadium cyclam complex 1 was then “merged” with the CXCR4 protein model into a separate
MOL2 file using SYBYLv6.9. Expected clashes were observed between Asp171 and the
sulfate group that were subsequently removed and two models of possible interaction were
produced. In Model 1 (Figure 7a), parameters were set with a view to investigate the possibility
of metal-carboxylate interactions with Asp171 in the binding site. In this case, the vanadium
center was fixed relative to the receptor and distance restraints of 2.14 Å (V-sulfate bond length)
with an average force constant of 500 kcal mol-1 Å-2 were applied to the postulated V-O bond
with Asp171, to represent metal-carboxylate binding. A second distance (1.609 Å) was set for
V=O to maintain the bond length and prevent stretching during the minimization process. Bad
contacts and geometries were then relieved by energy minimizing the region of the CXCR4
receptor surrounding the oxovanadium(IV) cyclam complex 1, (all amino acid residues with
a sphere radius of 5 Å from the cyclam ligand). In Model 2 (Figure 7b), no distance restraint
was applied between the vanadium center and carboxylate oxygens of Asp171, but docking
was otherwise undertaken as in Model 1.
Results
Synthesis and structure
The synthesis of the sulfate complex 1 was achieved by addition of 1 mol equiv of
VOSO4·xH2O to cyclam in methanol and refluxing for 24 h. The chloride complex 2 was
synthesized by addition of 1 mol equiv BaCl2 to 1 in aqueous solution to precipitate the sulfate
ligand as BaSO4. For complexes 3 and 4, xylylbicyclam was synthesized according to a
previously published procedure33 and the sulfate and chloride complexes were obtained by
procedures similar to those used for the corresponding cyclam complexes.
X-ray crystallographic data for complexes 1 and 2 were obtained at 150 K. Complex 1 (Figure
1a) crystallized as [V(IV)O(cyclam)SO4]·1.33CH3OH as the trans-III isomer (space group
R3c). A definition of the six possible configurations cyclam can adopt on complexing with a
metal ion (Chart 1) was proposed over 40 years ago11 and the trans-III configuration is
generally considered to be the most thermodynamically stable isomer. Similarly complex 2,
[V(IV)O(cyclam)Cl]Cl·CH3OH·1.5H2O (Figure 1b), also exhibited the trans-III configuration.
This complex crystallized with two molecules in the asymmetric unit (space group Cc). Both
cyclam complexes have a distorted octahedral geometry with sulfate in 1 and chloride in 2 as
ligands trans- to the axial V=O group. Complex 1 is neutral and the sulfate ligand coordinates
as a monodentate ligand. Two of the remaining sulfate oxygens form hydrogen bonds to two
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NH protons of the cyclam ring (Figure 1a). Crystal packing along the c axis of the unit cell
shows hydrogen bonding between adjacent macrocycles via the sulfate ligand as NH⋯O⋯HN.
In complex 2, crystal packing shows networks of hydrogen bonding between chlorine atoms,
ring protons and solvent molecules, contributing to the stability of the trans-III configuration.
The Cl-V=O angle (176.99(12)°) is significantly smaller than the corresponding O3SO-V=O
angle in the sulfate complex, 1 (177.83(9)°). The N(1)-V(15)-N(8) angle (165.46(16)°) is also
significantly smaller than the corresponding angle in complex 1, (166.88(7)°). Selected bond
lengths and angles are given in Table 1 for comparison with EXAFS data. V-N bond lengths
are comparable with similar examples for vanadium complexes found on searching the CCDC.
No previous examples of double H-bonding by sulfate as an axial ligand in cyclam-type
macrocycles appear to have been reported.
Infrared spectroscopy
IR spectroscopy for 1 showed a fairly high characteristic V(IV)=O vibrational stretch at 974
cm-1 suggesting that sulfate is weakly bound.20 The V(IV)=O stretch for the chloride species
2 is found at 988 cm-1. The V(IV)=O stretch for the sulfate bicyclam 3 was at 945 cm-1 and
for chlorido bicyclam 4 at 964 cm-1. Both stretches are lower for the bicyclams, consistent with
stronger binding of sulfate and chloride as suggested by the EPR data (vide infra).
X-ray absorption spectroscopy
Vanadium K-edge EXAFS data for the two bicyclam complexes 3 and 4 are compared with
those of the cyclam analogues 1 and 2 in Figure 2 which shows the R-space EXAFS and
calculated fits. Data were Fourier-transformed over k-ranges of at least 12.5 Ǻ-1; EXAFS-
derived parameters were obtained from R-space fits and are provided in Table 2. For the sulfate
complexes 1 and 3, two main first-coordination shells are clearly observed and are assigned as
V=O and V-N/O single scattering peaks. The anticipated scattering peak for the axial V-
OSO3 single scattering path is seemingly indistinguishable from that of the intense equatorial
V-N scattering feature due to similarities in scattering path length and phase. For the chlorido
complexes 2 and 4, three main first-coordination shells are observed in the data, assigned to
the V=O, V-N and V-Cl scattering pathways. The presence of the axial V-Cl scattering peak
reflects the marked differences between second-row and third-row scatterers and more
pronounced differences in bond distances. Statistical parameters from the best R-space fits and
all k-space data for the four complexes are given in the Supporting Information, Table S2,
Figure S2. The V K-edge XANES spectra for complexes 1-4 (Figure 3) are dominated by
intense pre-edge features due to formally electric dipole forbidden V3d←V1s transitions. The
non-centrosymmetric environment at the V center, enforced primarily by the presence of the
short V=O bond, allows for large 4p/3d mixing and thus intense pre-edge features for all
complexes. The overall nature of the ligand field is very similar for all cases, with subtle
differences in both transition intensities and energies (vide infra).
EPR spectroscopy
EPR spectroscopy revealed 8-line spectra associated with the 51V (I =7/2, 99.76% natural
abundance) quadrupolar nucleus, as expected for these 3d1 complexes. Calculated A and g-
values in spectra of room temperature and frozen solutions are shown in Tables 3 and 4 for
cyclam and bicyclam complexes respectively, and spectra for the cyclam complexes are shown
in Figure 4. Spectra for the bicyclam complexes are shown in Figure 5 (room temperature) and
Figure 6 (frozen solutions). Simulated EPR spectra for all samples are shown in Figure S3 of
the Supporting Information. Data were simulated using Bruker WINEPR Simphonia version
1.25 software and corrected as for the DPPH standard.31 Spectra were obtained in water and
methanol and compared with a reference complex where the 6th axial ligand X is expected to
be a solvent molecule. Synthesis procedures for solvent-exchanged complexes (solvent ligand
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denoted X) are detailed in the Supporting Information (S4). These complexes were synthesized
for EPR study from the species isolated by removing the chloride ligands from complexes 2
and 4.
Antiviral testing
All four compounds were tested for antiviral activity and results are shown in Supporting
Information Table S1 (cyclam complexes) and Table 5 (bicyclam complexes). The cyclam
complexes 1 and 2 were inactive (IC50 values >340 μM and >360 μM respectively). The
xylylbicyclam complexes 3 and 4 were highly active, although less active than AMD3100 and
the Zn-complex, Zn2-xylylbicyclam. Cytotoxicity levels are low, but slightly higher than for
AMD3100 and Zn2-xylylbicyclam.
Co-receptor docking
Oxovanadium(IV) cyclam complex 1 was docked into an homology model of CXCR4 and two
models of possible interaction were produced, in keeping with experimental observations from
EPR data. Differences in bonding-interactions for the two models were noticed.
In Model 1 (Figure 7a), parameters were set with a view to investigate the possibility of metal-
carboxylate interactions with Asp171 in the binding site. The vanadium center was fixed
relative to the receptor and distance restraints of 2.14 Ǻ (V-sulfate bond length) with an average
force constant of 500 kcal mol-1 Ǻ-2 were applied to the postulated V-O bond with Asp171. A
second distance (1.609 Ǻ) was set for V=O to maintain the bond length and prevent stretching
during the minimization process. Energy minimization was performed for the region of the
CXCR4 receptor surrounding the oxovanadium(IV) cyclam complex 1, i.e. all amino acid
residues with a sphere radius of 5 Ǻ from the cyclam ligand.
In the energy-minimized Model 1 (Figure 7a), hydrogen bonds are observed between
carboxylate oxygen atoms of Asp171 and two NH protons of the cyclam ring (∼2.0 Å and 2.2
Å) and a weak attraction is observed between V=O⋯H (2.3 Å) of the α-carbon proton from
Trp195 in the CXCR4 protein backbone. It is now recognised that CH⋯O hydrogen bonding
can play an important role in stabilizing protein structures.34 Additionally, Trp195 is involved
in a putative stacking (hydrophobic) interaction with the hydrocarbon backbone of the cyclam
ring, as previously suggested for the Zn2-bicyclam adduct.18 An optimum distance between
the vanadium center and the carboxylate oxygens of Asp171 gives rise to the possibility of a
coordinative bond.
The EPR data suggest that complexes 1 and 2 (unlike complexes 3 and 4) may have the 6th
(axial) ligand replaced by solvent. In light of these findings, Model 2 (Figure 7b) was produced,
such that no distance restraint was applied between the vanadium center and carboxylate
oxygens of Asp171 but docking was otherwise undertaken as in Model 1. In the energy-
minimized Model 2, potential hydrogen bonds are again observed between the carboxylate
oxygens and NH protons on the cyclam ring. Another weak attraction between the oxygen of
V=O and the proton of the α-carbon of Trp195 is also seen, but the distance between the
vanadium center and carboxylate oxygens of Asp171 (3.4Ǻ) is not compatible with formation
of a coordination bond.
Discussion
Crystallographic Studies
There appear to be no previous reports of the structures of 6-coordinate oxovanadium(IV)
complexes of cyclam or xylylbicyclam, although several vanadium structures do exist with
ligands such as chloride trans- to the V=O group. A 5-coordinate square-pyramidal oxo-
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vanadium(IV) cyclam has been reported,35 but no crystal structure is available for comparison
of V-N bond lengths. The V=O bonds in both 1 and 2 are short (1.6093(19) Å and 1.599(3) Å,
respectively)36 and somewhat intermediate between reported bond lengths for VIV and VV. A
search of the Cambridge Crystallographic Database (CCDC) revealed 21 six-coordinate
complexes with V(IV)=O groups and an additional 10 containing the V(V)=O group. Bond
lengths varied between 1.575 Å and 1.623 Å for VIV=O complexes, and between 1.614 Å and
1.640 Å for VV=O complexes. The V=O bond lengths of 1 and 2 are comparable with the V=O
bond in the square-pyramidal oxovanadium(IV) complex [VIVO(acac)2] (1.58 Å).37 The V—
O(sulfate) bond length of 2.1359(16) Å, is slightly longer than the V—O bond in [V(IV)O
(acac)2] (1.97 Å).37 In complex 2, the V—Cl bond length (2.6501(12) Ǻ) is significantly longer
those in examples of octahedral vanadium(IV) complexes with a chloride ligand trans- to V=O
(2.465 Ǻ,38 2.468 Ǻ39) and suggests that this ligand is weakly bound. A CCDC search for
similar vanadyl macrocyclic complexes with sulfate and chloride ligands in the 6th axial
position did not reveal any reported examples. Three vanadyl non-manrocyclic complexes with
a sulfate ligand were found and their bond lengths are compared in Table 6. In 1, the V=O
bond length is comparable with the trans-V=O(SO4) complex a36 trans-[VIVO(SO4)
(C23H34N4O2).5H2O, but significantly shorter than the trans-V=O(SO4) complex b38 trans-
[VIVO(SO4)(bipy)2] and longer than the cis-V=O(SO4) complex c40 cis-[VIVO(SO4)
(phen)2]. In 1, the V-O bond of the metal-sulfate interaction is shorter than that found for
complex a where the bond length is thought to be due to a significant trans-influence of the
vanadyl group. The V-O bond length in 1 is found to be significantly longer than for b and c.
In 1, the corresponding O-S bond length is longer than that found in a, but shorter than in b
and c.
Single crystals suitable for X-ray diffraction studies were not obtained for either the
oxovanadium(IV) xylylbicyclam complexes 3 or 4, although the latter did afford a
polycrystalline material.
Spectroscopic Studies
In the absence of crystallographic data, we have used V K-edge XAS to characterize
structurally and compare the solid-state structures of the cyclam and bicyclam complexes. Most
notably, a drastic change in the intensity of the V-Cl feature from the cyclam complex 2 to the
bicyclam complex 4 is seen (see Figure 2c,d) with a concomitant increase in the V-Cl distance
from 2.58 Ǻ to 2.63 Ǻ, respectively. The observed drop in intensity for the bicyclam complex
suggests either the loss of chloride-ligand occupancy in the solid state structure of 4 or a large
increase in disorder of the chloride ligand. To explore these two possibilities, different fits to
the EXAFS data were attempted. The best fit to the first coordination sphere yielded a
coordination environment consistent with VON4Cl0.5 corresponding to the loss of chloride
from one of the vanadyl units in the bicyclam complex. Enforcing the anticipated VON4Cl
coordination environment for each ring yielded a significantly poorer fit with a concomitant
doubling of σ2 for the V-Cl pathway (Table 2). Comparisons of these fits and their associated
goodness-of-fit parameters, suggests that partial loss of Cl ligation provides the most
reasonable interpretation of the data. The VON4Cl0.5 formulation could indicate partial
occupancy of the sixth coordination position or result from bridging chloride ligands to
generate oligomeric species in the solid state. This interpretation is consistent with the observed
lengthening of the V-Cl bonds by 0.05 Ǻ, and provides a rationale for problems encountered
during the synthetic work-up and recrystallization process, where precipitation of insoluble
products was observed. This is further supported by the near-edge XAS spectra (see Figure 3),
which show only subtle changes in the 3d manifold. The most notable change is a small shift
to higher energy (0.1-0.2 eV) in the pre-edge features of the bicyclams complexes as compared
to their cyclam analogues. Partial loss of the axial chloride ligand in 4 as compared to 2 would
be expected to result in a significant increase in the electric dipole-allowed component of the
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1s→3dz2 transition associated with the short V=O bond.41, 42 Given that the overall intensity
and relative energy distribution of the 1s→3d transitions remains essentially unchanged on
going from the cyclam to the bicyclam, implies that the overall ligand field is not perturbed
significantly.
EPR data for water and methanol solutions show that the g-values are close to 2 in all cases as
expected, as the unpaired electron is in a non-degenerate orbital. Any orbital angular
momentum is subsequently quenched resulting in a “spin-only” system. In addition, there
should be little mixing in of an orbital component from excited states through spin-orbit
coupling, leading to typical g-values close to, but slightly less than, 2. The unpaired electron
is in the dxy orbital and oriented between the N atoms in the cyclam plane. As dxy is essentially
non-bonding, any interaction with the nitrogen orbitals is very small and no resolved coupling
to nitrogen is seen. The cyclam complexes 1, 2 show very similar spectra to the X = H2O aqua
complex [VO(cyclam)(H2O)]2+ and may suggest that the 6th ligand has been replaced by
solvent. As the pH values of the solutions were acidic (pH = 3), it seems likely that the axial
ligand is water rather than hydroxide. This proposed ligand exchange is consistent with the X-
ray crystal structure data (Table 1) where bond lengths of the axial ligand trans- to the V=O
group suggest that the ligand is weakly bound. For the sulfate 3, and chloride 4 complexes,
significant differences are observed. Neither set of peaks for complex 3 show values of g and
A similar to that of the aqua complex, which suggests there is little substitution of the 6th ligand
by solvent unlike that proposed for the cyclam complexes. The low Aiso value of 84 (G) is at
the lower end of those reported for other vanadium(IV) species with O-donor ligands (85 to
110 G), although not the lowest reported (71 G).43-45 The values of giso (1.985, 1.983) fall
within reported ranges.44, 45 The separate set of signals observed and confirmed by simulation
may also suggest that each vanadium center is in a different environment, indicating that the
macrocyclic rings may adopt different configurations. The possibility of greater delocalization
onto the sulfate ligand may also result in the observed low Aiso value. Complex 4 clearly shows
two sets of peaks in the room temperature spectrum. Some degree of partial substitution of
chloride by water is indicated by the similar g-value and Aiso value (87 G) shown in Table 3.
A larger Aiso value was found for the second set of peaks found for complex 4, (Aiso = 115 G)
and suggests that a stronger interaction exists between the unpaired electron and the vanadium
center. The A-value, the hyperfine coupling constant, is related to the unpaired electron density
at the vanadium center. For this particular configuration, the unpaired electron may be more
localized on the vanadium than for the other configuration where Aiso = 87 G. An interesting
observation is that the average g and A values (energy units of cm-1) used to describe the frozen
solution spectra should approximate to the isotropic g and A values (cm-1) used to describe the
fluid solution spectra. There are some differences between these values in the complexes
described which may be explained by different solvent interactions of the complexes with water
and methanol, or may indicate that certain configurations are being ‘frozen out’ in the frozen
solution spectra. Large deviations from square-pyramidal geometry and also the nature of the
6th ligand can influence the A-value and π-donation into the dxy orbital can have a large effect.
In the light of these observations, it would appear that for the bicyclam complexes the retention
of, or alternatively slow exchange of the 6th axial ligand, appears to affect the value of A.
Previously, 2D NMR studies on zinc xylylbicyclam12 revealed an equilibrium mixture of
trans-I, trans-III and cis-V configurations in solution, but such experiments were not possible
with the paramagnetic vanadyl complexes 1 - 4.
Antiviral Testing
Transition-metal complexes show varying levels of anti-HIV activity which may arise partly
from a relationship between the metal-cyclam geometry and the number of binding site
interactions possible. Those favouring square planar geometries are found predominantly in
the trans-I configuration while octahedral complexes favour trans-III. Analysis of all nickel
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(II) cyclam complexes in the Cambridge Structural Database (CSD) shows the most common
configuration to be trans-III, so deemed the most stable configuration. Less than 23% of
octahedral nickel(II) complexes with a 1,4,8,11-substituted cyclam backbone adopted the
trans-I configuration compared with more than 75% preferring trans-III.46 This situation is
reversed for square-planar, square-pyramidal and trigonal-bipyramidal complexes with less
than 30% adopting trans-III and the majority showing a preference for the trans-I
configuration. Repeated analyses for copper(II) complexes resulted in similar findings.47 A
study of protein recognition of macrocycles has shown how the affinity of xylylbicyclam for
CXCR4 is enhanced further by binding to Ni(II) or Zn(II).48 Anti-HIV activity is very much
dependent upon the bound metal and a ZnII-xylylbicyclam complex showed slightly higher
biological activity than the metal-free ligand.
Our oxovanadium(IV)-xylylbicyclam complexes 3 and 4 possess high anti-HIV activity
against HIV-1 (IIIB) and HIV-2 (ROD) strains, with IC50 values in the range 1-5 μM for 3 and
0.1-0.3 μM for 4. The latter values are comparable with that of xylylbicyclam itself (AMD3100;
0.01 μM), but higher than that of Zn2-xylylbicyclam complex (0.003-0.009 μM). The reported
activity of metal xylylbicyclams follows the order: Zn(II) > xylylbicyclam ∼ Ni(II) > Cu(II)
> Co(III) ⋙ Pd(II), with the Pd(II) complex being virtually inactive.14, 17, 49 The oxovanadium
(IV)-cyclam complexes 1 and 2 are also inactive. By exploring the structures of protein-cyclam
adducts, insight into specific hydrophilic and hydrophobic interactions involved in the binding
of bicyclam to CXCR4 can be gained. In addition to interactions with aspartate and glutamate
residues, there is a possibility that the hydrocarbon backbone of the bicyclam rings is involved
in hydrophobic interactions with tryptophan residues, Trp195 and Trp283.50 This type of
interaction is comparable to that of the hydrophobic contact of the side-chain of proline with
tryptophan found at some protein-protein interfaces, commonly described as a Trp-Pro-Trp
sandwich.51 Recently, a configurationally-restricted bismacrocyclic CXCR4 receptor
antagonist was reported to have very high activity against HIV.9 The zinc complex of an
ethylene-bridged analogue of AMD3100 was found to have a lower EC50 value than AMD3100
and [Zn2-AMD3100]4+ and the highest reported activity against HIV (0.0025 μM vs 0.08
μM). It is expected that particular ring configurations may play a crucial part in determining
the antiviral activity of macrocyclic complexes. Metal complexes of cyclam and bicyclam in
solution give rise to several different configurational isomers, each dependent on the chirality
of the 4 ring nitrogens.8 The trans-I, II, III and cis-V configurations may all have a significant
influence on the bioactivity of metallo-macrocyclic antiviral compounds.9, 10, 12 The inactivity
of the cyclam complexes 1, 2 suggests that the aromatic linker of the bicyclam complexes may
play an important role in the co-receptor binding of complexes 3 and 4 and the anti-HIV
potency. Antiviral activity of cyclam and its derivatives is influenced by metal complexation
and subsequent binding to carboxylate oxygens of acidic (Glu and Asp) amino acid residues
in the binding site of CXCR4.18 Like complexes 1 and 2, Pd(II)-cyclam retains a trans-III
configuration in both solid state and solution and is inactive. Varying the counterion had no
effect on ring configuration and addition of acetate did not induce any configurational change
in vanadyl bicyclam.18 Our experiments show that additional axial ligands do not bind or bind
only weakly to 1 and 2 (see Supporting Information S5, for solution IR and conductivity
measurements). Our studies of these vanadyl cyclam complexes in aqueous solution suggest
that they are stable, although it would be interesting to carry our further studies in the presence
of potential competitor biomolecules. Our model (Figure 7) suggests that a weak attraction
between the vanadyl group oxygen (V=O) and the protein backbone resulting in a new binding
position for these cyclam complexes. Another study has shown that Co(III)-cyclam can adopt
the trans-III configuration in the solid state with axial acetate ligands, but solution studies show
the existence of three different configurations (trans-III, trans-I and a further unidentified
trans- configuration).18 This species is also inactive as the axial ligands exchange too slowly.
The bicyclam analogue formed intermediate species on reacting with acetate that equilibrated
to the trans-III isomer with time.13, 18 In terms of anti-HIV activity, it would appear that for
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V(IV)=O complexes one exchangeable ligand is enough providing there is a second cyclam
linked.
Co-receptor docking
Molecular modelling can offer a representation of possible binding interactions in the CXCR4
active site (see Figure 7). As bicyclam complexes 3 and 4 are active against HIV, their activity
may result from binding in an analogous fashion to zinc bicyclam12, through metal-carboxylate
interactions involving aspartate residues, Asp171 and Asp272, found in two separate binding
sites. However, no crystal structures were available for the oxovanadium(IV)-xylylbicyclam
complexes 3,4 and modelling was carried out using the oxovanadium(IV)-cyclam complex
1. Following manual docking and minimization, interactions were found that differed from
those in the the Zn2-xylylbicyclam-CXCR4 model studied previously12 (i.e. Zn(II)-
carboxylate 2.28 Ǻ compared with V(IV)-carboxylate 2.14 Ǻ in Model 1 and absence of this
interaction in Model 2). An additional H-bonding interaction is also seen (Figure 7),
specifically a weak attraction between the oxygen of V=O and the ά-carbon proton of Trp195
of CXCR4. A similarly docked oxovanadium(IV)-cyclam in the cis-V configuration in the
second binding site could assist in further accounting for the activity of the bicyclam complexes
3 and 4. An attempt was made to crystallize a single oxovanadium(IV)-cyclam attached to a
phenyl linker unit in order to investigate the effect of such a side-arm on the macrocycle
configuration, but was unsuccessful.
Conclusions
We have reported here the synthesis and characterization of four new vanadyl cyclam
complexes. The X-ray structures of the monocyclam complexes 1 and 2 appear to be the first
for vanadyl cyclams. The important role of cyclam NH groups in H-bonding is illustrated by
the double H-bonds formed in 1 with the uncoordinated oxygens of the axial sulfate ligand,
effectively locking the macrocycle in the trans-III configuration. EXAFS data suggest that the
xylylbicyclam chlorido complex 4 has a structure in which only one of the vanadyl centers has
an axial chlorido ligand or that there is a bridging ligand creating a chlorido-bridged oligomeric
species, consistent with difficulties in the synthesis. These structural differences may contribute
to the differences in the biological activity of the chlorido and sulfato complexes. EPR data
for aqueous solutions revealed two different environments for the vanadium metal center in
the xylylbicyclam complexes 3 and 4 and some exchange of axial sulfato and chloride ligands
with solvent. Complete exchange of the axial ligands for solvent was seen for the monocyclam
complexes 1 and 2. Modelling showed that a weak attraction between the V=O group and the
CXCR4 backbone may result in a longer distance between the vanadium center and carboxylate
oxygens of Asp171, and consequent loss of a coordination bond, which may account for the
inactivity of complexes 1 and 2. For the bicyclam complexes, these data indicate the possibility
that one ring is locked in a less-favorable binding mode with the second ring bound in an
alternative configuration providing further bonding interactions elsewhere, giving rise to the
level of bioactivity seen for complexes 3 and 4. This, in addition to the potential role of the
aromatic xylyl-linker in the bicyclam molecule may contribute to the anti-HIV activity.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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ORTEP (30% probability thermal ellipsoids) views of the sulfato complex 1 (left), and the
chlorido complex 2 (right).
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R-space (non-phase shift corrected) with calculated fits EXAFS data for (a) [VIVO(cyclam)
SO4)] 1, (b) [(VIVO)2(xylylbicyclam)(SO4)2] 3, (c) [VIVO(cyclam)Cl]+ 2, and (d)
[(VIVO)2(xylylbicyclam)(Cl2)]2+ 4. Key: black line, R-space; red line, R-space fit.
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Normalized solid-state XANES spectra of the pre-edge region of the four vanadyl compounds.
Top: [VIVO(cyclam)SO4)] 1 (⋯·), [(VIVO)2(xylylbicyclam(SO4)2] 3 (—). Bottom: [VIVO
(cyclam)Cl]+ 2 (⋯·), [(VIVO)2(xylylbicyclam(Cl)] + 4 (—). The arrow indicates the slight
increase in energy of the pre-edge feature when moving from vanadyl cyclam to bicyclam for
both the Cl and SO4 compounds.
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EPR spectra of sulfato oxovanadium(IV) cyclam 1. (a) In water at 298 K (the aqua complex,
see Table 3). (b) In frozen methanol at 77 K (sulfato complex).
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EPR solution spectra at 298 K of oxovanadium(IV) bicyclam complexes [(VO)2(bicyclam)
X2] where X = solvent, sulfate or chloride. (a) Aqua complex, (b) sulfato complex 3, and (c)
chloride complex, 4. The spectra clearly show two different environments for vanadium for
both the sulfato and chlorido complexes. The chlorido complex in particular shows significant
overlapping signals and may be due to different ring configurations in solution, or replacement
of one chlorido ligand by H2O.
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EPR spectra of oxovanadium(IV) bicyclam complexes [(VO)2(bicyclam)X2], where X = (a)
sulfate (complex 3) and (b) chloride (complex 4), as frozen methanolic solutions at 77 K.
Hyperfine couplings (A‖, z-axis) are seen for two sets of signals from complex 4 (A1 and A2)
and one set of signals from complex 3 (A1). These signals cannot all be attributed to the solvent-
exchanged complex [(VO)2(bicyclam)X2] where X = methanol, as only one set of signals
would be seen and both complexes would give rise to signals with the same A and g values. It
seems likely that only one V center of the bicyclam complexes undergoes exchange.
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Molecular model of {VIVO(cyclam)} bound to the co-receptor CXCR4, based on the trans-III
configuration of [VIVO(cyclam)SO4] 1 found in its X-ray structure. (a) Model 1 (left), vanadyl
cyclam forms a coordinative bond (2.14 Å) and other H-bonds with Asp171. A weak
V=O⋯H (2.3 Å) attraction is also seen between the α-carbon proton from Trp195 and the
vanadyl oxygen atom. (b) Model 2 (right), lacks the coordination bond to the carboxylate of
Asp171 (V⋯O 3.4 Å).
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Configurations of metallocyclams and structures of cyclam, xylylbicyclam and complexes
1-4. AMD3100 is the octahydrochloride salt (xylylbicyclam.8HCl).
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Table 1
Selected Bond Distances (Å) and Angles (degrees) for Complexes 1 and 2
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